According to the latest report by IMARC Group, titled "Biodefense Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032," the global biodefense market size reached US$ 16.8 Billion in 2023. The term biodefense refers to a broad range of precautions and tactics implemented to safeguard people against the intentional or unintentional release of biological agents that might hurt or endanger the environment, agriculture, or public health. It includes a variety of initiatives meant to stop, identify, and address biological hazards, such as naturally occurring infectious illnesses, bioterrorism occurrences, and outbreaks of newly or re-emerging diseases. Its main objective is to protect human and animal health by reducing the negative effects that biological threats have on individuals, entire communities, and society as a whole. This multidisciplinary field brings together the efforts of public health organizations, medical specialists, researchers, academics, law enforcement, first responders, intelligence agencies, and several other stakeholders to build a resilient and effective defense system.
Global Biodefense Market Trends:
The escalating demand for biological weapons majorly drives the global market. This can be supported by the rising concerns about the deliberate release of pathogens, the potential for widespread outbreaks, and the persistent threat of bioterrorism. Along with this, the increasing occurrence of new and evolving infectious diseases, such as the coronavirus disease (COVID-19), is encouraging governments and numerous private organizations to heavily invest in biodefense to improve preparedness, surveillance, diagnostics, and a rapid response to these emerging infectious diseases, which is significantly supporting the market. Additionally, the growing funding activities to support research and development activities, the acquisition of advanced biodefense systems, and the establishment of robust infrastructure for surveillance and response are influencing the market favorably. In addition, the growing awareness regarding biodefense solutions, including personal protective equipment (PPE), vaccines, therapeutics, and surveillance systems, is propelling the market. Furthermore, continuous advancements in biotechnology, genomics, synthetic biology, and data analytics are creating a positive market outlook. Some of the other factors driving the market include increasing collaboration and partnerships and the rising importance of biosecurity. On account of the aforementioned factors, the market value is projected to reach US$ 28.0 Billion by 2032, expanding at a CAGR of 5.81% during 2024-2032.
Market Summary:
- On the basis of the vaccine type, the market has been divided into anthrax, smallpox, botulism, and others.
- Based on the biothreat detection device, the market has been segmented into samplers, detectors/triggering devices, identifiers, assays, and others.
- On the basis of the end-user, the market has been divided into hospitals and clinics, ambulatory care centers, and others.
- Region-wise, the market has been segmented into North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.
- The competitive landscape of the market has been studied in the report with the detailed profiles of the key players. Some of these players include Achaogen Inc., Alnylam Pharmaceuticals Inc., Altimmune Inc. (PharmAthene Inc.), Bavarian Nordic A/S, Cleveland BioLabs Inc., Dynavax Technologies Corporation, Dynport Vaccine Company LLC (General Dynamics Corporation), Elusys Therapeutics Inc., Emergent Biosolutions Inc., Ichor Medical Systems Inc., Ology Bioservices Inc., and SIGA Technologies, Inc.
Report Scope:
Report Features |
Details |
Base Year of the Analysis |
2023 |
Historical Period |
2018-2023 |
Forecast Period |
2024-2032 |
Units |
US$ Billion |
Segment Coverage |
Vaccine Type, Biothreat Detection Device, End-User, Region |
Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
Achaogen Inc., Alnylam Pharmaceuticals Inc., Altimmune Inc. (PharmAthene Inc.), Bavarian Nordic A/S, Cleveland BioLabs Inc., Dynavax Technologies Corporation, Dynport Vaccine Company LLC (General Dynamics Corporation), Elusys Therapeutics Inc., Emergent Biosolutions Inc., Ichor Medical Systems Inc., Ology Bioservices Inc. and SIGA Technologies, Inc. |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800